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Abstract
A key challenge in genomics is to identify genetic variants that distinguish patients with dif-
ferent survival time following diagnosis or treatment. While the log-rank test is widely used
for this purpose, nearly all implementations of the log-rank test rely on an asymptotic ap-
proximation that is not appropriate in many genomics applications. This is because: the two
populations determined by a genetic variant may have very different sizes; and the evalua-
tion of many possible variants demands highly accurate computation of very small p-values.
We demonstrate this problem for cancer genomics data where the standard log-rank test
leads to many false positive associations between somatic mutations and survival time. We
develop and analyze a novel algorithm, Exact Log-rank Test (ExaLT), that accurately com-
putes the p-value of the log-rank statistic under an exact distribution that is appropriate for
any size populations. We demonstrate the advantages of ExaLT on data from published
cancer genomics studies, finding significant differences from the reported p-values. We an-
alyze somatic mutations in six cancer types from The Cancer Genome Atlas (TCGA), find-
ing mutations with known association to survival as well as several novel associations. In
contrast, standard implementations of the log-rank test report dozens-hundreds of likely
false positive associations as more significant than these known associations.
Author Summary
The identification of genetic variants associated with survival time is crucial in genomic
studies. To this end, a number of methods have been proposed to computing a p-value
that summarized the difference in survival time of two or more population. The most
widely used method among these is the log-rank test. Widely used implementations of the
log-rank test present a systematic error that emerges in most genome-wide applications,
where the two populations have very different sizes, and the accurate computation of very
small p-values is required due to the evaluation of a number of candidate variants. Consid-
ering cancer genomic applications, we show that the systematic error leads to many false
positive associations of somatic variants and survival time. We present and analyze a new
algorithm, ExaLT that accurately computes the p-value for the log-rank test under a
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distribution that is appropriate for the parameters found in genomics. Unlike previous ap-
proaches, ExaLT allows to control the accuracy of the computation. We use ExaLT to ana-
lyze cancer genomics data from The Cancer Genome Atlas (TCGA), identifying several
novel associations in addition to well known associations. In contrast, the standard imple-
mentations of the log-rank test report a huge number of presumably false
positive associations.
Introduction
Next-generation DNA sequencing technologies are now enabling the measurement of exomes,
genomes, and mRNA expression in many samples. The next challenge is to interpret these
large quantities of DNA and RNA sequence data. In many human and cancer genomics stud-
ies, a major goal is to find associations between an observed phenotype and a particular vari-
able (e.g., a single nucleotide polymorphism (SNP), somatic mutation, or gene expression)
from genome-wide measurements of many such variables. For example, many cancer sequenc-
ing studies aim to find somatic mutations that distinguish patients with fast-growing tumors
that require aggressive treatment from patients with better prognosis. Similarly, many human
disease studies aim to find genetic alleles that distinguish patients who respond to particular
treatments, i.e. live longer. In both of these examples one tests the association between a DNA
sequence variant and the survival time, or length of time that patients live following diagnosis
or treatment.
The most widely approach to determine the statistical significance of an observed difference
in survival time between two groups is the log-rank test [1, 2]. An important feature of this test,
and related tests in survival analysis [3], is their handling of censored data: in clinical studies,
patients may leave the study prematurely or the study may end before the deaths of all patients.
Thus, a lower bound on the survival time of these patients is known. Importantly, many studies
are designed to test survival differences between two pre-selected populations that differ by one
characteristic; e.g. a clinical trial of the effectiveness of a drug. These populations are selected to
be approximately equal in size with a suitable number of patients to achieve appropriate statis-
tical power (Fig 1A). In this setting, the null distribution of the (normalized) log-rank statistic
is asymptotically (standard) normal; i.e. follows the (standard) normal distribution in the limit
of infinite sample size. Thus, nearly every available implementation (e.g., the LIFETEST pro-
cedure in SAS, and the survdiff R function, and coin and exactRankTests packages
in R and SPlus) of the log-rank test computes p-values from the normal distribution, an ap-
proximation that is accurate asymptotically (see S1 Text).
The design of a genomics study is typically very different from the traditional clinical trials
setting. In a genomics study, high-throughput measurement of many genomics features (e.g.
whole-genome sequence or gene expression) in a cohort of patients is performed, and the goal
is to discover those features that distinguish survival time. Thus, the measured individuals are
repeatedly partitioned into two populations determined by a genomic variable (e.g. a SNP) and
the log-rank test, or related survival test, is performed (Fig 1B). Depending on the variable the
sizes of the two populations may be very different: e.g. most somatic mutations identified in
cancer sequencing studies, including those in driver genes, are present in< 20% of patients [4–
9]. Unfortunately, in the setting of unbalanced populations, the normal approximation of the
log-rank statistic might give poor results.
While this fact has been noted in the statistics literature [10–12], it is not widely known, and
indeed the normal approximation to the log-rank test is routinely used to test the association
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of somatic mutations and survival time (e.g. [13, 14] and numerous other publications). A sec-
ond issue in genomics setting is that the repeated application of the log-rank test demands the
accurate calculation of very small p-values, as the computed p-value for a single test must be
corrected for the large number of tests; e.g. through a Bonferroni or other multiple-hypothesis
correction. An inaccurate approximation of p-values will result in an unacceptable number of
false positives/negative associations of genomic features with survival. These defining charac-
teristics of genomics applications, unbalanced populations and necessity of highly-accurate p-
values for multiple-hypothesis correction, indicate that standard implementations of the log-
rank test are inadequate.
We propose to compute the p-value for the log-rank test using an exact distribution deter-
mined by the observed number of individuals in each population. Perhaps the most famous use
of an exact distribution is Fisher’s exact test for testing the independence of two categorical var-
iables arranged in a 2×2 contingency table. When the counts in the cells of the table are small,
the exact test is preferred to the asymptotic approximation given by the χ2 test [15]. Exact tests
for comparing two survival distributions have received scant attention in the literature. There
are three major difficulties in developing such a test. First, there are multiple observed features
that determine the exact distribution including the number of patients in each population and
Fig 1. Difference between survival analysis in a clinical setting with balanced populations and genomics setting, with unbalanced populations. (A)
In a typical clinical study, two pre-selected groups of similar size are compared. Because the groups are balanced and each has a suitable number of
patients, the asymptotic approximation (normal distribution) used in common implementations of the log-rank test gives an accurate approximation of the
exact distribution, resulting in accurate p-values. (B) In a genomics study, the two groups are defined by a genetic variant. In many cases, the sizes of the
groups are unbalanced, with one group being much larger than the other. In this situation, the asymptotic distribution does not accurately approximate the
exact distribution of the log-rank statistic, and the resulting p-values computed from the tail of the distribution (see inset) are inaccurate.
doi:10.1371/journal.pcbi.1004071.g001
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the observed censoring times. With so many combinations of parameters it is infeasible to pre-
compute distribution tables for the test. Thus, we need an efficient algorithm that computes the
p-value for any given combination of observed parameters. Second, we cannot apply a standard
Monte-Carlo permutation test to this problem since we are interested in very small p-values
that are expensive to accurately estimate with such an approach. (By the accurate estimation of
a p-value using Monte-Carlo permutation test, we mean the calculation of a p-value and a con-
fidence interval of the same order of magnitude of the p-value.) Third, there are two possible
null distributions for the log-rank test, the conditional and the permutational [2, 16–18]. While
both of these distributions are asymptotically normal, the permutational distribution is more
appropriate for genomics settings [2, 19], as we detail below. Yet no efficient algorithm is
known to compute the p-value of the log-rank test under the exact permutational distribution.
We introduce an efficient and mathematically sound algorithm, called ExaLT (for Exact
Log-rank Test), for computing the p-value under the exact permutational distribution. (ExaLT
computes an estimate of the p-value under the exact permutational distribution; for this reason
we denote the p-value obtained from ExaLT as an exact p-value, in contrast to the approximate
p-value obtained from asymptotic distributions.) The run-time of ExaLT is not function of the
p-value, enabling the accurate calculation of small p-values. For example, obtaining an accurate
estimate of p 10−9 is required if one wants to test the association of 1% of the human genome
(e.g., the exome) with survival, and using a standard MC approach requires (with the Clopper-
Pearson confidence interval estimate) the evaluation of 1011 samples, that for a population
of 200 patients requires> 8 days; in contrast ExaLT is capable of estimating p 10−13 on 200
patients in< 2 hours. In contrast to heuristic approaches (see Materials and Methods) ExaLT
provides rigorous guarantees on the relation between the estimated p-value and the correct p-
value; moreover, it returns a conservative estimate of the p-value, thus guaranteeing rigorous
control on the number of false discoveries. We test ExaLT on data from two published cancer
studies [20, 21], finding substantial differences between the p-values obtained by our exact test
and the approximate p-values obtained by standard tools in survival analysis. In addition, we
run ExaLT on somatic mutation and survival data from The Cancer Genome Atlas (TCGA)
and find a number of mutations with significant association with survival time. Some of these
such as IDH1mutations in glioblastoma are widely known; for others such as BRCA2 and
NCOA3mutations in ovarian cancer there is some evidence in the literature; while the remain-
ing are genuinely novel. Most of these are identified only using the exact permutational test of
ExaLT. In contrast, the genes reported as highly significant using standard implementations of
the log-rank test are not supported by biological evidence; moreover, these methods report
dozens-hundreds of such likely false positive associations as more significant than known
genes associated with survival. These results show that our algorithm is practical, efficient, and
avoids a number of false positives, while allowing the identification of genes known to be asso-
ciated with survival and the discovery of novel, potentially prognostic biomarkers.
Results
Accuracy of Asymptotic Approximations
We first assessed the accuracy of the asymptotic approximation for the log-rank test on simu-
lated data from a cohort of 500 patients with a gene gmutated in 5% of these patients, a fre-
quency that is not unusual for cancer genes in large-scale sequencing studies [4–7]. We
compared the survival times of the population P(g) of patients with a mutation in g to the sur-
vival of the population PðgÞ of patients with no mutation in g. We computed p-values using R
survdiff on multiple random instances (in order to obtain a distribution for the p-value of
g) in which P(g) and PðgÞ have the same survival distribution. S1 Fig shows that the p-values
Survival Statistics in Genome-Wide Studies
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computed by the asymptotic approximation are much smaller than expected under the null hy-
pothesis, with the smallest p-values showing the largest deviation from the expected
uniform distribution.
The inaccuracy of the asymptotic log-rank test results in a large number of false discoveries:
for example, considering a randomized version of a cancer mutation dataset (S1 Table) in
which no mutation is associated with survival (i.e. no true positives), the asymptotic log-rank
test reports 110 false discoveries (Bonferroni correction) or 291 false discoveries (False Discov-
ery Rate (FDR) correction), with significance level α = 0.05 (Fig 2). We found that for the num-
ber of patients of interest to current genomic studies, the inaccuracy of the asymptotic log-rank
test results mostly from the imbalance in the sizes of the two populations, rather than the total
number of patients or the number of patients in the smaller population (see S1a Fig, S1b Fig,
S1c Fig, S1d Fig, and S1 Text).
Fig 2. Differences between observed and expected p-values from different forms of the log-rank test
on a randomized cancer dataset consisting of somatic mutations in 6184 genes. The p-values for the
genes should be distributed uniformly (green line), since there is no association between mutations and
survival in this random data. Asymptotic approximations of the log-rank statistic (purple and blue) yield p-
values that deviate significantly from the uniform distribution, incorrectly reporting many genes whose
mutations are significantly associated with survival. In particular, the asymptotic log-rank test in R reports 110
genes with significant association, using a Bonferroni corrected p-value < 0.05 (black line), or 291 genes with
significant association using a less conservative FDR = 0.05. In contrast, the exact test makes no
false discoveries.
doi:10.1371/journal.pcbi.1004071.g002
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An Efficient Algorithm for the Exact Log-Rank Test
As noted above, there are two exact distributions for the log-rank test in the literature: the per-
mutational distribution [2] and the conditional distribution [16]. We developed an algorithm,
Exact Log-rank Test (ExaLT), to compute the p-value of the log-rank statistic under the exact
permutational distribution. On simulations of cancer data, we found that the p-values from the
permutational exact test are significantly closer to the empirical p-values than the p-values ob-
tained from the conditional exact test (S2 Fig and S1 Text). Thus, we derived a fully polynomial
time approximation scheme (FPTAS) for computing the p-value under the permutational dis-
tribution. In contrast to heuristic methods that do not provide any rigorous guarantee on the
quality of the approximation of the p-value, our algorithm provides an approximation that is
guaranteed to be within a user defined distance from the p-value, for any given sample size, in
polynomial time. Furthermore, the output of our scheme is always a conservative or valid p-
value estimate. The C++ implementation of ExaLT (that can be called from R) is available at
https://github.com/fvandin/ExaLT.
Published Cancer Studies
To demonstrate the applicability of ExaLT we compared the p-values from the exact distribu-
tion to p-values from the asymptotic approximation reported in two recently published cancer
genomics studies [20, 21]. Huang et al. [20] divides patients into groups defined by the number
of risk alleles of five single nucleotide polymorphisms (SNPs), and compares the survival distri-
bution of the resulting populations. In one comparison, the survival distribution of 2 patients
(13% of total) with at most 2 risk alleles was compared with the survival distribution of 14 pa-
tients with more than 2 risk alleles, and a p-value of 0.012 is reported. Thus, this association is
significant at the traditional significance level of α = 0.05. However, ExaLT computes an exact
p-value of 0.17, raising doubts about this association. In another comparison patients at a dif-
ferent disease stage were considered, and the division of the patients into groups as above re-
sulted in comparing the survival distribution of 8 patients (17% of total) with the survival
distribution of 40 patients, and a p-value of 6×10−6 is reported. In contrast, ExaLT computes
an exact p-value of 2×10−3, a reduction of three orders of magnitude in the significance level.
Additional comparisons are shown in the S1 Text. Therefore in these cases the asymptotic ap-
proximation underestimates the exact permutational p-values resulting in associations deemed
more significant than what is supported by the data.
In [21], the survival distribution of 14 glioblastoma patients (11% of total) with somatic
IDH1 or IDH2mutations was compared to the survival distribution of 115 patients with wild-
type IDH1 and IDH2. The reported p-value from the asymptotic approximation is 2×10−3,
while the exact permutational p-value is 5×10−4, indicating a stronger association between so-
matic mutations in IDH1 or IDH2 and (longer) survival than reported. Notably, this same asso-
ciation has been reported in three other glioblastoma studies [22–24].
TCGA Cancer Data
We analyzed somatic mutation and survival data from studies of six different cancer types (S1
Table) from The Cancer Genome Atlas (TCGA). For the range of parameters of these datasets
our simulations show that the asymptotic approximation is not accurate for genes with muta-
tion frequency 10%; we then did not considered genes with mutation frequency> 10%. We
also discarded genes mutated with frequency< 1%. For each mutated gene, we first obtained
an estimate ~p of the p-value using an MC approach, and if ~p  0:01 we used ExaLT to compute
a controlled approximation of the p-value. We compared the p-value obtained in this way with
the one obtained by using the asymptotic approximation as computed by the R package
Survival Statistics in Genome-Wide Studies
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survdiff (S2 Table, S3 Table, S4 Table, S5 Table). Fig 3 shows the exact p-values and the R
survdiff p-values for the glioblastoma multiforme (GBM) dataset and ovarian serous ade-
nocarcinoma (OV) dataset. The p-values for the other datasets are shown in S3 Fig.
For most datasets the asymptotic p-values obtained from R survdiff are very different
from the ones obtained with the exact p-values obtained by ExaLT, and the ranking of the
genes by p-value is very different as well (see S1 Text). For example, in GBM none of the top 26
genes reported by R are in the list of the top 26 genes reported by the exact permutational test.
Since genomics studies are typically focused on the discovery of novel hypotheses that will be
further validated, this striking difference in the ranking of genes by the two algorithms is im-
portant: a poor ranking of genes by their association with survival will lead to many false dis-
coveries undergoing additional experimental validation. While some of genes ranked in the top
10 by ExaLT are known to have mutations associated with survival (e.g., IDH1 in GBM and
BRCA2 in OV), none of the top 10 genes reported by R survdiff (S5 Table) have mutations
known to be associated with survival. R survdiff ranks dozens-hundreds of presumably
false positives associations as more significant than these known genes. Moreover, R surv-
diff reports extremely strong association with survival for many of these higher ranked, but
likely false positive, genes; e.g., in uterine corpus endometrial carcinoma (UCEC), 13 genes
have p< 10−8 and an additional 19 genes have p< 10−5, but none of these have a known asso-
ciation with survival.
The top 10 genes reported by ExaLT contain several novel associations that are supported
by the literature and are not reported using R survdiff. In GBM, ExaLT identifies IDH1
(p 3×10−4), VARS2 (p 5×10−3) and GALR1 (p 6×10−3), among others. As noted above,
the association between mutations in IDH1 and survival has been previously reported in GBM
[21–24]. A germline variant in VARS2 has been reported to be a prognostic marker, associated
with survival, in early breast cancer patients [25]. The expression of GALR1 has been reported
to be associated with survival in colorectal cancer [26], and its inactivation by methylation has
been associated with survival in head and neck cancer [27, 28]. In OV, ExaLT identifies BRCA2
(p 4×10−3) and NCOA3 (p 10−3), and others. Germline and somatic mutations in BRCA2
Fig 3. Comparison of the p-values of association between somatic mutations and survival time for
TCGA glioblastoma (GBM) and ovarian (OV) datasets. Each data point represents a gene. (A)
Comparison of the R survdiff p-values and the exact permutational p-values for the GBM dataset. (B)
Comparison of the R survdiff p-values and the exact permutational p-values for the OV dataset.
doi:10.1371/journal.pcbi.1004071.g003
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(and BRCA1) have been associated with survival in two ovarian cancer studies [4, 29]. A poly-
morphism in NCOA3 has been associated with breast cancer [30], and its amplification has
been associated with survival in ER-positive tumors [31].
Thus, the exact test implemented by ExaLT appears to have higher sensitivity and specificity
in detecting mutations associated with survival on the sizes of cohorts analyzed in TCGA. Fi-
nally, we note that the exact conditional test obtains results similar to R survdiff, confirm-
ing that the the exact permutational test implemented by ExaLT is a more appropriate exact
test for genomics studies. (See S1 Text.) We have also assessed the difference between the result
obtained using ExaLT and the results obtained using the asymptotic permutational test
(S2 Table, S3 Table, S4 Table, S5 Table). In this case the difference in the ranking of genes is re-
duced but still present; in particular, in COADREAD 4 of the top 10 genes identified by ExaLT
are not among the top 10 genes found using the asymptotic permutational test. Moreover,
there are some genes for which there is a large difference in the p-value computed by ExaLT
and the p-value from the asymptotic permutational test; for example, in UCEC data CTGF is
ranked first by both ExaLT and the asymptotic permutational test, but it has p = 9.6×10−5 by
ExaLT and p = 8.3×10−10 by the asymptotic permutational test.
Discussion
In this work we focus on the problem of performing survival analysis in a genomics setting,
where the populations being compared are not defined in advance, but rather are determined
by a genomic measurement. The two distinguishing features of such studies are that the popu-
lations are typically unbalanced and that many survival tests are performed for different mea-
surements, requiring highly accurate p-values for multiple hypothesis testing corrections. We
show empirically that the asymptotic approximations used in available implementations of the
log-rank test produce anti-conservative estimates of the true p-values when applied to unbal-
anced populations, resulting in a large number of false discoveries. This is not purely a phe-
nomenon of small population size: the approximation remains inaccurate even for a large
number of samples (e.g., 100) in the small population. This inaccuracy makes asymptotic ap-
proximations unsuitable for cancer genomic studies, where the vast majority of the genes are
mutated in a small proportion of all samples [4–6] and also for genome-wide association stud-
ies (GWAS) where rare variants may be responsible for a difference in drug response or other
phenotype, even if it is possible that for extremely large genomic studies (e.g., with 100000 pa-
tients) the asymptotic approximations would provide results accurate enough even for imbal-
anced populations (e.g., when the small population is 1%).
The problem with the log-rank test for unbalanced populations has previously been re-
ported [10, 11], but the implications for genomics studies have not received attention. Note
that the issue of unbalanced populations is further exacerbated by any further subdivision of
the data: e.g. by considering mutations in specific locations or protein domains; by considering
the impact of mutations on a specific therapeutic regimen; by testing the association of muta-
tions with survival in a particular subtype of cancer; by grouping into more than two popula-
tions; or by correcting for additional covariates such as age, stage, grade, etc. All of these
situations occur in genomics studies.
We considered the two versions of the log-rank test, the conditional [16] and the permuta-
tional [2], and we found that the exact permutational distribution is more accurate in genomics
settings. We introduce ExaLT, the first efficient algorithm to compute highly accurate p-values
for the exact permutational distribution. We implemented and tested our algorithm on data
from two published cancer studies, showing that the exact permutational p-values are
Survival Statistics in Genome-Wide Studies
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significantly different from the p-values obtained using the asymptotic approximations. We
also ran ExaLT on somatic mutation and survival data from six cancer types from The Cancer
Genome Atlas (TCGA), showing that our algorithm is practical, efficient, and allows the identi-
fication of genes known to be associated with survival in these cancer types as well as novel as-
sociations. We note that ExaLT can be employed as part of permutation tests that require the
computation of p-values for a large number of genomic features measured on the same set of
patients [12]. While the current implementation of ExaLT handles ties in survival times by
breaking them arbitrarily, its extension to different tie breaking strategies and their impact is
an important future direction.
The method we propose can be generalized to assess the difference in survival between
more than two groups, by considering the exact permutational distribution for the appropriate
test statistic. For this reason, our method can be adapted to test the difference in survival be-
tween groups of patients that have homozygous or heterozygous mutations, or to test whether
the presence of a group of genomic features has a different effect on survival compared to the
presence of the single genomic features. For the same reason, our method can incorporate cate-
gorical covariates, while it is unclear how methods based on the log-rank test, as ours, can in-
corporate continuous covariates or how they can be used to assess specific (e.g., additive)
models of interactions between genomic features and survival.
While our focus here was the log-rank test, our results are relevant to more general survival
statistics. First, in some survival analysis applications, samples are given different weights; our
algorithm can be easily adapted to a number of these different weighting schemes. Second, an
alternative approach in survival analysis is to use the Cox Proportional-Hazards model [3].
While in the Cox regression model one can easily adjust for categorical and continuous covari-
ates, it is not clear how to incorporate continuos potential confounders in the log-rank test that
we consider. While this constitutes a limitation of our method, the Cox regression models is
often used to compare two populations even when no adjustment for confounders is per-
formed. In this case, the significance of the resulting coefficients in the regression is typically
done using a test that is equivalent to the log-rank test, and thus our results are relevant for this
approach as well. See S1 Text and S4 Fig.
The challenges of extending multivariate regression models to the multiple-hypothesis set-
ting of genome-wide measurements is not straightforward. Direct application of such a multi-
variate Cox regression will often not give reasonable results as: there are a limited number of
samples and a large number of genomic variants; and many variants are rare and not associated
with survival. Witten and Tibshirani (2010) [32] recently noted these difficulties for gene ex-
pression data stating that: “While there are a great number of methods in the literature for iden-
tification of significant genes in a microarray experiment with a two-class outcome . . . the topic
of identification of significant genes with a survival outcome is still relatively unexplored.” We
propose that exact tests such as the one provided here will be useful building blocks for more
advanced models of survival analysis in the genomics setting.
Materials and Methods
Background: The Log-Rank Test
We focus here on the two-sample log-rank test of comparing the survival distribution of two
groups, P0 and P1. Let t1 < t2 < . . .< tk be the times of observed, uncensored events; in case of
ties, we assume that they are broken arbitrarily. Let Rj be the number of patients at risk at time
tj, i.e. the number of patients that survived (and were not censored) up to this time, and let Rj,1
be the number of P1 patients at risk at that time. Let Oj be the number of observed uncensored
events in the interval (tj−1, tj], and let Oj,1 be the number of these events in group P1. If the
Survival Statistics in Genome-Wide Studies
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survival distributions of P0 and P1 are the same, then the expected value E½Oj;1 ¼ Oj Rj;1Rj . The
log-rank statistic [1, 2] measures the sum of the deviations of Oj,1 from the expectation,
V ¼Pkj¼1 Oj;1  Oj Rj;1Rj
 
.
(In some clinical applications one is more interested in either earlier or later events. In that
case the statistic is a weighted sum of the deviations. Our results easily translate to the weighted
version of the test.) Under the null hypothesis of no difference in the survival distributions of
the two groups, E[V] = 0, and Pr(jVj  jvj) is the p-value of an observed value v. Two possible
null distributions are considered in the literature, the permutational distribution and the condi-
tional distribution (see S5 Fig).
Permutational Log-Rank Test
In the permutational log-rank test [2], the null distribution is obtained by assigning each pa-
tient to population P0 or P1 independently of the survival time. Let n be the total number of pa-
tients, and n1 the number of patients in group P1. We consider the sample space of all
n
n1
 !
possible selections of survival times and censoring information from the observed data for the
n1 patients of group P1. Each such selection is assigned equal probability
n
n1
 !1
.
Conditional Log-Rank Test
In the conditional log-rank test [16], the null distribution is defined by conditioning on Oj, Rj,
and Rj,1 for j = 1,. . ., k. If at time tj there are a total of Rj patients at risk, including Rj,1 patients
in P1, then under the assumption of no difference in the survival of P0 and P1 the Oj events at
time tj are split between P0 and P1 according to a hypergeometric distribution with parameters
Rj, Rj,1, and Oj.
Choice of Null Distribution and Estimation of p-values
We considered the two versions of the log-rank test, the conditional [16] and the permutational
[2], that differ in the null distribution they consider. The conditional log-rank test is preferred
in clinical trials because it does not assume equal distribution of censoring in the two popula-
tions. This is important in clinical trials when patients in the two groups are subject to different
treatments that may affect their probability of leaving the trial. However, unequal censoring is
not a concern in genomic studies, since we do not expect a DNA sequence variant to have an
impact of the censoring in the population. Moreover, in the genomic studies of interest to this
work, the patients are not assigned to the two populations at the beginning of the study, and
the measured individuals are instead repeatedly partitioned into two populations determined
by a genomic variable. Therefore under the null hypothesis of no association between a geno-
mic variable and survival time the two populations can be assumed to have the same distribu-
tion of potential follow-up times, and the correction for unequal follow-up, that is a concern in
clinical trials [33], is not required in our scenario. In both versions of the test, under the null
distribution the prefix sums of the log-rank statistic define a martingale, and by the martingale
central limit theorem [3], the normalized log-rank statistic has an asymptoticN(0,1) distribu-
tion. (Sometimes the log-rank test is described using an asymptotic χ2 distribution; the two ver-
sion of the tests are related, and our results hold for the version of the log-rank test based χ2
distribution as well (S1 Fig).) The normalizing variance is different in the two null distributions
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and this may be reflected in differences between the p-values obtained from the two null distri-
butions, but asymptotically the two variances are the same [17], leading to the same p-values in
the two versions of the test for large balanced populations. Therefore, the distinction between
the two versions of the test is largely ignored in practice, where most papers that use the log-
rank test or software packages that implement the test do not document the specific version
test they consider. This can be explained, in part, by the widespread use of the log-rank in
other scenarios, like clinical trials, where the issues specific to genomic settings (e.g., the imbal-
ance between populations) do not arise. The differences between the tests are also rarely dis-
cussed in the literature, although there is some discussion [17, 19] on which variance is the
appropriate one to use to compute p-values from the asymptotic approximation.
In the case of small and unbalanced populations, the two null distributions yield different p-
values, and the normal approximation gives poor estimates of both (S1 Fig). On simulations of
cancer data, we found that the p-values from the permutational exact test are closer to the em-
pirical p-values than the p-values obtained from the conditional exact test (S2 Fig and S1 Text).
Moreover, we prefer the permutational null distribution because it better models the null hy-
pothesis for mutation data.
While the exact computation of p-values in the conditional null distribution can be comput-
ed in polynomial time using a dynamic programming algorithm [33], no polynomial time algo-
rithm is known for the exact computation of the p-value in the permutational null distribution:
current implementations are based on a complete enumeration algorithm, making its use im-
practical for large number of patients (e.g., the StatXactmanual recommends using the
enumeration algorithm only when the number of samples is at most 20). Several heuristics
have been developed for related computations including: saddlepoint methods to approximate
the mid-p-values [34], methods based on the Fast Fourier Transform (FFT) [35–37], and
branch and bound methods [38]. Such heuristics are shown to be asymptotically correct, con-
verging to the correct p-value as the number of samples and computation time grows to infini-
ty. However, no explicit bounds are known for the accuracy of the computed p-value when
these heuristics are applied to a fixed sample size and under a bounded computation time.
Therefore, when run on a specific input, these heuristics do not provide guarantees on the rela-
tion between the p-value and the approximation they report. Given the systematic error we re-
port below for the standard asymptotic implementation of the log-rank test, we argue that such
guarantees are essential in this and many similar settings.
ExaLT
We developed an algorithm, Exact Log-rank Test (ExaLT), to compute the p-value of the log-
rank statistic under the exact permutational distribution. In particular, we designed a fully
polynomial time approximation scheme (FPTAS) for computing the p-value under the permu-
tational distribution. Our algorithm gives an explicit bound on the error in approximating the
true p-value, for any given sample size, in polynomial time. Furthermore, the output of our
scheme is always a conservative or valid p-value estimate. Conceptually, our algorithm is simi-
lar to the one presented in [39].
Since the log-rank statistic depends only on the order of the events and not on their actual
times, we can without loss of generality treat the survival data (including the censored times) as
an ordered sequence of events, with no two patients having identical survival times. Let nj =
jPjj, for j = 0,1, be the number of patients in each population and let n = n0+n1 be the total
number of patients. We represent the data by two binary vectors x 2 {0,1}n and c 2 {0,1}n,
where xi = 1 if the ith event was in P1 and xi = 0 otherwise; ci = 0 if the ith event was censored
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and ci = 1 otherwise. Note that n1 ¼
Pn
i¼1 xi. In this notation the log-rank statistic is
V ¼ Vðx; cÞ ¼
Xn
j¼1
cj xj 
n1 
Pj1
i¼0 xi
n jþ 1
 
 ð1Þ
Let VtðxÞ ¼
Pt
j¼1 cjðxj 
n1
Pj1
i¼0 xi
njþ1 Þ be the test statistic V(x) at time t. Note that since n, n1,
and c are fixed, the statistic depends only on the value of x. Assume the observed log-rank sta-
tistic has value v. The p-value of the observation v is the probability Pr(jV(x)j  jvj) computed
in the probability space in which the n1 events of P1 are uniformly distributed among the
n events.
For any 0 t n and 0 r n1, let Pðt; r; vÞ ¼ PrðVtðxÞ  vand
Pt
i¼1 xi ¼ rÞ denote the
joint probability of Vt(x) v and exactly r events from P1 occur in the first t events. Let
Qðt; r; vÞ ¼ PrðVtðxÞ  vand
Pt
i¼1 xi ¼ rÞ denote the joint probability of Vt(x) v and ex-
actly r events from P1 occur in the first t events.
At time 0: P(0,r,v) = 1 if r = 0 and v 0, otherwise P(0,r,v) = 0. Similarly Q(0,r,v) = 1 if r = 0
and v 0, otherwise Q(0,r,v) = 0.
Given the values of P(t,r,v) for all v and r, we can compute the values of P(t+1,r,v) using the
following relations: If ct+1 = 1 then
Pðt þ 1; r; vÞ ¼ 1 n1  r
n t
 
P t; r; v þ n1  r
n t
 
þ n1  ðr  1Þ
n t P t; r  1; v  1
n1  ðr  1Þ
n t
  

If ct+1 = 0 then
Pðt þ 1; r; vÞ ¼ 1 n1  r
n t
 
Pðt; r; vÞ þ n1  ðr  1Þ
n t Pðt; r  1; vÞ
Analogous equations hold for Q(t,r,v).
The process defined by these equations guarantees that the n events always include n1 events of
P1. Thus, the p-value of the observation v is given by Pr(jV(x)j  jvj) = P(n,n1,−jvj)+Q(n,n1,jvj).
For fixed t and r, P(t+1,r,v) and Q(t+1,r,v) are step functions. For example, if ct+1 = 1, then
as we vary v, P(t+1,r,v) changes only at the points in which P t; r  1; v  1 n1ðr1Þ
nt
  
or
P t; r; v þ n1r
nt
 
change values. Thus, we only need to compute the function P(t+1,r,v) at these
points. At t = 0 the function P(0,r,v) assumes up to 2 values. If P(t,r,v) assumesm(t,r) values
and P(t,r−1,v) assumesm(t,r−1) values, then P(t+1,r,v) assumes up tom(t,r)+m(t,r−1) values.
Similar relations hold for P(t+1,r,v) when ct+1 = 0, and for computing Q(t,r,v) in the two
cases. Thus, in n iterations the process computes the exact probabilities P(n,r,v) and Q(n,r,v),
but it may have to compute probabilities for an exponential number of different values of v in
some iterations.
We construct a polynomial time algorithm by modifying the above procedure to compute
the probabilities of only a polynomial number of values in each iteration. We first observe that
since the probability space consists of
n
n1
 !
equal probability events, all non-zero probabili-
ties in our analysis are nn1 . For " > 0, fix "1 such that (1−"1)−n = 1+". Note that 1 = O(/n).
We discretize the interval of possible non-zero probabilities ½nn1 ; 1, using the values (1−"1)k,
for k = 0,. . .,ℓ, where ‘ ¼ n1 logn
logð11Þ ¼ Oð1nn1lognÞ. The approximation algorithm estimates P
(t,r,v) with a step function ~Pðt; r; vÞ defined by a sequence of ℓ points vtk;r, k = 0,. . .,ℓ, such that
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vtk;r is an estimate for the largest v such that P(t,r,v) (1−"1)k. We prove that if iteration t com-
putes a function ~Pðt; r; vÞð1 1Þt  Pðt; r; vÞ  ~Pðt; r; vÞ, then starting from ~Pðt; r; vÞ the t+1
iteration computes an estimate ~Pðt þ 1; r; vÞð1 1Þtþ1  Pðt þ 1; r; vÞ  ~Pðt þ 1; r; vÞ. (S6
Fig provides the intuition for how the approximation at time t+1 is computed from the approx-
imation at time t.) Thus, after n iterations we have an -approximations for P(n,n1,v). Similar
computations obtain an -approximation for Q(n,n1,v). The details of the algorithm and analy-
sis are given in the S1 Text.
We implemented the FPTAS in our software ExaLT and evaluated its performance as n and
" varies, and by comparing its running time with the running time of the exhaustive enumera-
tion algorithm for the permutational test (S7 Fig). Our implementation of the FPTAS is very ef-
ficient, with significant speed-up compared to the exhaustive algorithm.
We note that, given parameters n,n1,", and given the censoring vector c, ExaLT computes
the entire distribution of the test statistic under the null hypothesis. Once this distribution is
computed, it can be used for any vector x 2 {0,1}n with n1 ¼
Pn
i¼1 xi and the same censoring
vector c. We therefore implemented a variant of ExaLT that given multiple vectors x’s for the
same set of patients (e.g., mutation data from multiple genes on the same set of patients) as
input stores the distributions already computed and uses these distributions for quick lookup
whenever possible. (This feature cannot be used when the vectors x’s are defined for different
sets of patients, for example when there are missing gene measurements or genotypes.)
Synthetic Data
We used synthetic data to assess the accuracy of the asymptotic approximations. We generated
data as follow: when no censoring was included, we generated the survival times for the pa-
tients from an exponential distribution, and the group labeling (mutated or not) were assigned
to patients independently of their survival time; when censoring in c% of the patients was in-
cluded, the survival times come from the exponential distribution with expectation equal to 30,
and censoring variable from an exponential distribution resulting in c% of censoring (in
expectation).
We used synthetic data to compare the empirical p-value and the p-values from the exact
tests as well. In this case we generated synthetic data using two related but different procedures.
In the first procedure, we mutate a gene g in exactly a fraction f of all patients. In the second
procedure, we mutated a gene g in each patient independently with probability f. The second
procedure models the fact that mutations in a gene g are found in each patient independently
with a certain probability. In both cases the survival information is generated from the same
distribution for all patients, as described above.
Mutation and Clinical TCGA Data
We analyzed somatic mutation and clinical data, including survival information, from the pub-
lic TCGA data portal (https://tcga-data.nci.nih.gov/tcga/). In particular we considered single
nucleotide variants and small indels for colorectal carcinoma (COADREAD), glioblastoma
multiforme (GBM), kidney renal clear cell carcinoma (KIRC), lung squamous cell carcinoma
(LUSC), ovarian serous adenocarcinoma (OV), and uterine corpus endometrial carcinoma
(UCEC). We restricted our analysis to patients for which somatic mutation and survival data
were both available. We only considered genes mutated in> 1% of patients. We also removed
genes with mutation frequency> 10%. Since genes mutated in the same set of patients would
have the same association to survival, they are all equivalent for an automated analysis of asso-
ciation between mutations and survival; we then collapsed them intometagenes, recording the
genes that appear in a metagene. For the remaining genes we first obtained an estimate ~p of the
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p-value using a MC approach, and we then used ExaLT (with " = 1.5) to compute the exact per-
mutational p-value whenever ~p was 0.01. For any given TCGA dataset we used the variant of
ExaLT that stores previously computed distribution and uses them for quick lookup whenever
possible. The runtime was reasonable for the dataset we analysed (e.g., 310 minutes for the
COADREAD dataset).
The results published here are in whole or part based upon data generated by The Cancer
Genome Atlas pilot project established by the NCI and NHGRI. Information about TCGA and
the investigators and institutions who constitute the TCGA research network can be found at
http://cancergenome.nih.gov/.
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